id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-1888-0008,FDA,FDA-2016-E-1888,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2019-03-08T05:00:00Z,2019,3,2019-03-08T05:00:00Z,,2019-03-08T12:52:46Z,,0,0,0900006483acc287
FDA-2016-E-1888-0006,FDA,FDA-2016-E-1888,"Determination of Regulatory Review Period for Purposes of Patent
Extension; DARZALEX",Notice,Determinations,2018-02-20T05:00:00Z,2018,2,2018-02-20T05:00:00Z,2018-08-21T03:59:59Z,2018-02-20T15:02:40Z,2018-03342,0,0,0900006482f45478
FDA-2016-E-1888-0005,FDA,FDA-2016-E-1888,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-06-07T04:00:00Z,2017,6,2017-06-07T04:00:00Z,,2017-06-07T16:35:58Z,,0,0,09000064826a2084
FDA-2016-E-1888-0004,FDA,FDA-2016-E-1888,Letter from U.S. Patent and Trademark Office to FDA,Other,Letter(s),2016-12-27T05:00:00Z,2016,12,2016-12-27T05:00:00Z,,2016-12-27T18:01:50Z,,0,0,09000064824380f0
FDA-2016-E-1888-0003,FDA,FDA-2016-E-1888,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-08-26T04:00:00Z,2016,8,2016-08-26T04:00:00Z,,2016-08-26T13:26:19Z,,0,0,090000648219e752
FDA-2016-E-1888-0002,FDA,FDA-2016-E-1888,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2016-07-05T04:00:00Z,2016,7,2016-07-05T04:00:00Z,,2016-07-05T18:10:16Z,,0,0,09000064820810e0
FDA-2016-E-1888-0001,FDA,FDA-2016-E-1888,Patent Extension Application from Nelson Mullins Riley & Scarborough LLP (on behalf Genmab A/S),Other,Application,2016-07-05T04:00:00Z,2016,7,2016-07-05T04:00:00Z,,2016-07-05T18:10:07Z,,0,0,09000064820810d8